Breakthroughs such as CAR-T cell therapy in the treatment of mantle cell lymphoma could help patients overcome drug resistance and ultimately live longer, according to Dr. Michael Wang.
Drug resistance is one major roadblock in cancer researchers’ way of improving patient outcomes in mantle cell lymphoma (MCL) treatment, according to Dr. Luhua (Michael) Wang.
However, promising developments in the treatment of MCL and other B-cell lymphomas could help patients overcome drug resistance and live longer lives.
“To overcome drug resistance, we’ve had three major technology achievements in the past few years. In the past, we always used chemotherapy,” said Wang, who is a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center in Houston, explaining that the rapid advancements included targeted therapies, immunotherapies and cell therapies.
At the 2019 American Society of Clinical Oncology Annual (ASCO) Meeting, Wang discussed study findings and the technological advances in B-cell lymphoma treatment space that provide hope for patients with MCL of overcoming drug resistance and potentially live longer.